Judge Dismisses Tercica, Genentech Patent Suit Vs. Insmed

Law360, New York (April 18, 2005, 12:00 AM EDT) -- A federal judge has dismissed Tercica, Inc.’s and Genentech, Inc.’s patent infringement lawsuit against rival Insmed Inc. over its SomatoKine growth hormone treatment.

The U.S. District Court for the Northern District of California granted Insmed's motion to dismiss the amended complaint as originally written, but granted the plaintiffs leave to file another amended complaint within thirty days.

“Insmed will evaluate any new amended complaint when it is received and will determine at that time how to proceed,” Insmed said in a statement.

Tercica and its licensee,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.